Date |
Content |
12/27/2021 |
Weekly Broadcast: NRG-HN009, NRG-GU011 |
12/20/2021 |
Weekly Broadcast NRG-GU009, NRG-GY012, NRG-DT001, NRG-LU002, NRG-BR003, NRG-BR004, NRG-BR007, NRG-GI004, and NRG-GI005 |
12/14/2021 |
NRG-GY012: Action Letter and Amendment 5 |
12/13/2021 |
Weekly Broadcast: NRG-GU011, RTOG 1308, NRG-CC005, RTOG 1308, NRG-BN010, NRG-BN011, NRG-BR004, NRG-BR007, NSABP B-55, NRG-GI005, NRG-GU008 |
12/10/2021 |
RFP for Gyn studies |
12/9/2021 |
NRG-CC005/FORTE - Amendment 3 Activation |
12/6/2021 |
Weekly Broadcast: NRG-BN011, NRG-GU007, NRG-GU008, NRG-BN001, NRG-BR007, NSABP B-55, NRG-BR003, NRG-BR004, NRG-GI004, NRG-GI005, NRG-CC005, NRG-CC008, NRG-LU005 |
11/29/2021 |
Weekly Broadcast: NRG-LU004, NRG-LU005, NSABP B-55, NRG-CC003, NRG-GU010 |
11/24/2021 |
NSABP B-55/Olympia Data Lock |
11/22/2021 |
Weekly Broadcast: NRG-DT001, NRG-LU005, NRG-BN001, NRG-BR007, NRG-BR003, NRG-BR004, NRG-GI004, NRG-GI005, NRG-CC005, NRG-GU010 |
11/18/2021 |
NRG-DT001: Cohort A, Permanently Closed to Accrual |
11/15/2021 |
Weekly Broadcast: NRG-GY018,NRG-GY020, NRG-LU002, NRG-HN009, NRG-BN010, NRG-BR004, NRG-CC005, NRG-GU008, NRG-GU007 |
11/10/2021 |
NRG-LU002: Notice of Temporary Closure to Accrual |
11/9/2021 |
Pembrolizumab Action Letter - Amendments for NRG-GY018, NRG-GY020, NRG-LU002 |
11/8/2021 |
Weekly Broadcast: NRG-GU010, NRG-GU007, NRG-GY021, NRG-BN005, NRG-BR004, NRG-BR007, NRG-CC005, NRG-LU006 |
11/4/2021 |
NRG-GU007: Temporary Closure |
11/4/2021 |
FORTE/NRG-CC005 Overview Sessions |
11/3/2021 |
NRG-GU010 Protocol Activation |
11/1/2021 |
Deadline Extended for PSC Applications |
11/1/2021 |
Weekly Broadcast: NRG-BR004, NRG-BR007, NRG-CC005, NRG-GY020, NRG-GY024, NRG-HN001, NRG-LU006 |
10/28/2021 |
NRG-HN007: Closure |
10/27/2021 |
NRG-HN009 Protocol Activation |
10/25/2021 |
Weekly Broadcast:NRG-BR007, NRG-CC005, NRG-HN006 |
10/18/2021 |
Weekly Broadcast: GOG-0278, NRG-GY009, NRG-HN002, NRG-CC005, NRG-GY004, NRG-GI005 |
10/14/2021 |
NRG-GY009 Closure and GOG-0278 Closure
|
10/11/2021 |
Weekly Broadcast: FORTE (NRG-CC005), GOG-0278, NRG-GY005, NRG-GY009, NRG-GY012, |
10/6/2021 |
FORTE Study NRG-CC005 Activation |
10/4/2021 |
Weekly Broadcast: NRG-CC007CD, GOG-0278, NRG-GY012, NRG-HN001, NRG-LU002 |
9/30/2021 |
Olaparib Action Letter - Amendments for NRG-GY004, NRG-GY005, NRG-GY012, NRG-GY021, NRG-GY023 |
9/28/2021 |
PSC Call for Applications |
9/27/2021 |
Weekly Broadcast: NRG-GY009, NRG-GI004, GOG-0274/RTOG 1174, NRG-GY012 |
9/20/2021 |
Annual Call for Committee Member Applications |
9/20/2021 |
Weekly Broadcast: NRG-BN001, NRG-CC008, NRG-BR007 |
9/14/2021 |
NRG-GU007: Reopening of Dose Level 2 (phase I) for 1 additional patient |
9/13/2021 |
Weekly Broadcast: NRG-DT001, NRG-GI005, NRG-GY018, NRG-LU002, NRG-LU005 |
9/10/2021 |
NRG-DT001: Cohort A, Dose Level 3 (Expansion Cohort): Temporarily Closed to Accrual |
9/8/2021 |
NRG-HN008: Recruitment Flyer |
9/7/2021 |
Weekly Broadcast: NRG-GY006, NRG-GY024, NRG-BR002, NRG-HN002, NRG-GI005, NRG-BN007 |
8/30/2021 |
Weekly Broadcast: NRG-GY005, NRG-BN010, NRG-GI005, NRG-GY018, NRG-GY022 |
8/27/2021 |
Dr. Yom appointed H&N Cancer Committee Chair |
8/25/2021 |
NRG-GY022 Recruiting MALE patients |
8/23/2021 |
Weekly Broadcast: GOG-0278, NRG-GY022, NRG-BR004, NRG-BR007, NSABP B-55, NRG-GI005, NRG-GY021, NRG-LU005 |
8/16/2021 |
Weekly Broadcast: NRG-GY012, NRG-GI007, NRG-LU002, NRG-BR004, NRG-GU008, NRG-HN004 |
8/9/2021 |
Weekly Broadcast: NRG-GY022, NRG-LU002, NRG-BR004, NRG-CC009, NRG-GI005, RTOG 1216, NRG-LU007, NRG-LU005 |
8/2/2021 |
Weekly Broadcast: NRG-BR004, RTOG 1216, NRG-HN004, NSABP B-55 |
7/30/2021 |
NRG-HN004 Temporary Closure |
7/30/2021 |
NRG-BR004 Amendments 3-4 Activation |
7/26/2021 |
Weekly Broadcast: NRG-GY018, NRG-BN010, NRG-GU009, NRG-HN007, NRG-LU002 |
7/19/2021 |
Weekly Broadcast: NRG-HN008 |
7/12/2021 |
Weekly Broadcast: NRG-BR004 |
7/6/2021 |
Weekly Broadcast: NRG-BN010, NRG-GU008, NRG-GU009, NRG-CC005, NRG-GI004 |
7/6/2021 |
NRG-BN010: Protocol Activation |
7/1/2021 |
NRG-GU009 Temporary Closure FAQs |
6/29/2021 |
CCTG CE.7 Shipments to TTDR |
6/28/2021 |
Weekly Broadcast: NRG-GU008, NRG-GU009, NRG-GY020, NRG-GI004, NRG-GY009, RTOG 1216, NRG-LU002, NRG-LU005, NRG-LU007, NRG-BR003, NRG-BR004, NRG-HN001 |
6/28/2021 |
Dr. Le appointed NRG Group Chair |
6/24/2021 |
NRG-GU008 and GU009 Temporary Closure |
6/24/2021 |
Atezolizumab Action Letter - Amendments for NRG-GI004, NRG-GY009, NRG-LU002, NRG-LU005, NRG-LU007, RTOG 1216 |
6/23/2021 |
NRG-BR004 Notice of Temporary Registration & Accrual Hold |
6/21/2021 |
Weekly Broadcast: NRG-GI005, NRG-HN007 |
6/21/2021 |
NRG-LU004 Study Closure |
6/18/2021 |
NRG-BR004 Temporary Registration & Accrual Hold |
6/14/2021 |
Weekly Broadcast: NRG-BR007, NRG-GI004 |
6/14/2021 |
NRG-GI005 Reopening (US) & Amendment #1 |
6/14/2021 |
NRG-HN007 Temporary Closure to Accrual |
6/7/2021 |
Weekly Broadcast: NRG-BR007, NSABP B-55, NRG-GI004, GOG-0247/RTOG 1174/OUTBACK |
6/7/2021 |
NRG-BR007: Protocol Activation |
6/4/2021 |
NSABP B-55 Amd 7 Activation |
6/1/2021 |
Weekly Broadcast: NRG-GI004, NRG-GY023 |
5/28/2021 |
NRG at ASCO 2021 Virtual Meeting |
5/27/2021 |
NRG-GY012 Action Letter |
5/24/2021 |
Weekly Broadcast: NRG-GY006, NRG-GI004, NRG-HN006 |
5/17/2021 |
Weekly Broadcast: NRG-GY006, NRG-GI004 |
5/10/2021 |
Weekly Broadcast: NRG-GU007, NRG-GY006, NRG-CC003, NSABP B-55, NRG-HN008, NRG-LU005 |
5/5/2021 |
NRG-GU007: Temporary Closure to Accrual |
5/3/2021 |
Weekly Broadcast: NRG-GY006, NRG-LU003, NRG-BN007, S1914, CCTG CE.7, NRG-HN007, NRG-GY018, NRG-GY019, NRG-GY020, NRG-LU004 |
4/26/2021 |
Weekly Broadcast: NRG-GY023, NRG-GU007, GOG-0225 |
4/19/2021 |
Weekly Broadcast: NRG-LU005, NSABP B-55, GOG-0225, NRG-HN007 |
4/12/2021 |
NRG-CC007CD Amendment 4 |
4/12/2021 |
Weekly Broadcast: GOG-0225, NRG-HN005 |
4/5/2021 |
Weekly Broadcast: NRG-LU003, NRG-GU007, NRG-GY018, NRG-GY20, NRG-LU005 |
4/1/2021 |
NRG-LU003 Temporary Closure |
3/30/2021 |
NSABP B-55 Electronic Signatures Follow-up |
3/29/2021 |
Weekly Broadcast: NRG-BN007, NRG-HN007, NRG-BR003, NRG-BR004, NRG-LU007 |
3/22/2021 |
Weekly Broadcast: GOG-0252, NRG-GY011, NRG-GY020 |
3/16/2021 |
NSABP B-55 Electronic Signatures Follow-up |
3/15/2021 |
Weekly Broadcast: NRG-GY009, RTOG 1112, NRG-GY006, NRG-DT001, NRG-BN007, NRG-HN005, NRG-HN007, NRG-GU007, NRG-HN004, RTOG 1216, NRG-CC009 |
3/10/2021 |
RTOG 1112: Closure and Dear Patient/Dear Investigator Letters |
3/8/2021 |
Weekly Broadcast: NRG-RTOG 1108, NRG-GY018 |
3/4/2021 |
RTOG 1008: Closure Notice |
3/1/2021 |
Weekly Broadcast: NRG-CC008, NRG-CC009, RTOG 1112, NSABP B-55, NRG-LU007 |
2/24/2021 |
NRG-RTOG 1112: Closure Notice and Dear Patient/Dear Investigator Letters |
2/24/2021 |
NRG-CC009: Protocol Activation |
2/23/2021 |
NRG COVID-19 Vaccine Statement |
2/22/2021 |
Weekly Broadcast: NRG-CC004, NRG-GI002, NRG-RTOG 1216, NRG-BN009 |
2/17/2021 |
NSABP B-55/OlympiA Interim Analysis |
2/15/2021 |
Weekly Broadcast: NRG-GY009, NRG-HN004, NRG-BN009, NRG-BR003 |
2/9/2021 |
NRG-GY009: Temporary Suspension |
2/8/2021 |
Weekly Broadcast; NRG-GY016, NRG-GY022; NRG-LU004, NRG-BR003, NRG-BR005, NSABP B-55, NRG-GI004, NRG-GI005, NRG-GI007, NRG-GU007, NRG-GU008, NRG-GU009 |
2/2/2021 |
NSABP B-55 Electronic Signatures |
2/1/2021 |
Weekly Broadcast: NRG-GI004 |
1/29/2021 |
NRG-GI004 Re-Activation |
1/25/2021 |
Weekly Broadcast: NRG-BR004, NRG-CC007CD |
1/18/2021 |
Weekly Broadcast: NRG-GU007 |
1/11/2021 |
Weekly Broadcast: GOG-0209, NRG-GI006, NRG-GY018, NRG-HN007, NRG-BN007, NRG-BN009 |
1/4/2021 |
Weekly Broadcast: NRG-GY020, NRG-GI005, NRG-BR004, NRG-CC008 |